The impact of price controls on rare disease medicines access and lessons for the US
US policy has long recognized this challenge, beginning with the Orphan Drug Act of 1983 and continuing with recent exemptions for certain orphan indications...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Strategy in rare disease requires specialist expertise and understanding. CRA understands the unique challenges that rare disease companies face, and we implement a distinctive approach to help drive their success.
Follow us on LinkedIn: CRA on Rare Disease
CRA’s experience stems from hundreds of rare disease engagements across many therapeutic areas.
US policy has long recognized this challenge, beginning with the Orphan Drug Act of 1983 and continuing with recent exemptions for certain orphan indications...
RADAR contains all orphan drugs (ODs) that received European Medicines Agency (EMA) marketing authorisation between July 1, 2013, and September 30, 2024. For...
Annabelle Fowler presents the CRA paper titled “An Analysis of Medicaid CPI Rebates and the Sustainability of U.S. Generic Markets.” Ashutosh Mishra presents...
CRA is a proud sponsor of the the largest and most established orphan drug & rare disease meeting of its kind across the globe. From cell and gene therapy,...
CRA and leading European payer experts hosted a 30-minute virtual webinar to explore how growing competitive dynamics are reshaping the rare diseases market...
CRA had four posters accepted at the conference. Kirsten Axelsen and Charlotte Poon present their poster titled “Assessing the economic burden of rare disease...